Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial Model Innovation Key To Lowering China Compliance Risks

This article was originally published in PharmAsia News

Executive Summary

Balanced scorecards, big data, and platform strategies are among the new tools being employed by pharma companies ramping up compliance and lowering risks in China, where market access remains challenging and pricing pressures persistent. Such commercial model innovation should also improve physician interaction while providing new medical solutions, said executives at a recent RDPAC gathering in Beijing.

You may also be interested in...



2016 Review: Pricing, R&D Issues Dominate China Commercial Arena

2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.

Winter Olympics Test China's 'Zero COVID' Limits, Treatment Constraints

Amid China’s increasingly inward-looking and dual circulation economic policies, the Beijing Winter Olympics provide rare insight into policymakers’ handling of a global event.

Soft Capsule, Hard Truth: Will Chugai Lawsuit Usher In New Era Of China Patent Linkage?

Few drug patent infringement cases go to court in China, where a murky and lengthy process deters many from pursuing litigation. But a newly enacted Patent Law with patent linkage provisions is spurring a rise in infringement lawsuits, with one recent case involving a major Japanese pharma firm underscoring the remaining challenges.

Topics

Related Companies

UsernamePublicRestriction

Register

SC089636

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel